Techne, a manufacturer of biological research products, has agreed to buy diagnostics outfit Bionostics for $104 million, a deal it expects to close early next year.
Exact Sciences is looking to haul in $63.7 million through a stock sale, cash the company needs to get its stool-based cancer diagnostic through the FDA process and onto U.S. shelves.
In 15 years, Germany's Epigenomics has experienced a heady series of ups and downs. The Berlin-based diagnostics company went public on the Frankfurt stock exchange in 2004 and raised €41.6 million. It merged with a Seattle operation that is now its U.S. arm and gained CE marks for a colon cancer early-detection diagnostic and a lung cancer confirmatory assay. But over the last two years, there was also the restructuring. Read more >>
As Siemens banks on personalized medicine to help turn around its healthcare business, the technology giant said its new companion diagnostics deal with Johnson & Johnson is a step in the right direction.
Quest Diagnostics wasted no time after the U.S. Supreme Court ruled that human genes are a product of nature and cannot be patented. Hours after the historic decision, the company disclosed it will offer tests that spot two key breast cancer genetic mutations at the center of the judicial ruling.
While Thermo Fisher is busy raising cash to seal its $13.6 billion fate, Life Technologies is expanding its heft in South Korea, buying up another distributor in the growing market.
Natera has signed a deal to get its non-invasive prenatal test distributed across Switzerland and Scandinavia, another advance for the young company as it touts Panorama to be the most reliable diagnostic in the now-crowded space.
A U.K. study knocks the use of an angiogram on its own to diagnose and treat heart disease patients, blaming it for flawed results in at least 25% of all cases. Teaming it with a second diagnostic known as a fractional flow reserve could eliminate the problem, however, the trial finding concludes.
Medicare is the biggest buyer of lab-based diagnostic tests in the U.S., and the program overpaid by about $910 million in 2011, according to a federal report, lining the pockets of companies like Quest Diagnostics and LabCorp.
Alere's fifth-largest stockholder is pressuring the company to sell off some of its units and focus on its profitable diagnostics business, taking issue with the Alere's board nominations and reluctance to change.